In the past few years, the lack of real time world data has hampered the efforts to get the FDA to approve CBD’s potential medical benefits. The regulatory body has always demanded for data collected from the real lives of CBD users to enhance the efforts for CBD approval.
Well, that is set to change in the near future. Two scientists have been selected to lead the consumer research study. Dr. Keith Aqua who is a medical doctor from Miami is partnering with Dr. Jeff Lombardo a pharmacist specializing in toxicology from New York to lead the nationwide clinical trials.
The research is aimed at studying the effects of regular CBD consumption on the liver in adults. It will look into all the three types of CBD extracts; CBD isolate, broad spectrum and full spectrum.
In the past several studies have been conducted by individual hemp and CBD companies. The FDA has taken little consideration into the findings.
The current study is developed by a Colorado firm called ValidCare that provides clinical and market research for hemp and health industries. The study has been given approval by the Institutional Review Board which is an organization that oversees human cynical studies.
Currently, a number of CBD and hemp companies have enlisted to sponsor the real time data collection and analysis. The enlisted companies are recruiting consumers of their products for the study.
Here is a list of the companies sponsoring the study:
- SunMed CBD
- Boulder Botanical & Bioscience Labs
- CBD American Shaman
- Charlotte’s WebHempFusion
- Infinite CBD
- Columbia CareAsterra Labs
- Global Widget
- Medterra CBD
- Care by Design
The latest study has been designed to tick all the boxes that the FDA may require to take it more seriously. According to Dr. Lombardo, the study may incorporate up to 1000 participants. It runs for 60 days and is slated to end by 2020.